PL3439653T3 - Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1 - Google Patents

Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1

Info

Publication number
PL3439653T3
PL3439653T3 PL17779801T PL17779801T PL3439653T3 PL 3439653 T3 PL3439653 T3 PL 3439653T3 PL 17779801 T PL17779801 T PL 17779801T PL 17779801 T PL17779801 T PL 17779801T PL 3439653 T3 PL3439653 T3 PL 3439653T3
Authority
PL
Poland
Prior art keywords
inhibitors
administering
combination
tumor burden
reducing tumor
Prior art date
Application number
PL17779801T
Other languages
English (en)
Inventor
Israel Charo
Heiyoun JUNG
Thomas J. Schall
Penglie Zhang
Original Assignee
Chemocentryx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx, Inc. filed Critical Chemocentryx, Inc.
Publication of PL3439653T3 publication Critical patent/PL3439653T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
PL17779801T 2016-04-07 2017-04-06 Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1 PL3439653T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662319689P 2016-04-07 2016-04-07
PCT/US2017/026290 WO2017176965A1 (en) 2016-04-07 2017-04-06 Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
EP17779801.4A EP3439653B1 (en) 2016-04-07 2017-04-06 Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

Publications (1)

Publication Number Publication Date
PL3439653T3 true PL3439653T3 (pl) 2021-07-05

Family

ID=59999231

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17779801T PL3439653T3 (pl) 2016-04-07 2017-04-06 Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1

Country Status (20)

Country Link
US (2) US10568870B2 (pl)
EP (1) EP3439653B1 (pl)
JP (2) JP2019510832A (pl)
KR (1) KR102370704B1 (pl)
CN (1) CN109310677A (pl)
AR (1) AR108202A1 (pl)
AU (1) AU2017246460B2 (pl)
BR (1) BR112018070361A2 (pl)
CA (1) CA3019391A1 (pl)
DK (1) DK3439653T3 (pl)
ES (1) ES2864148T3 (pl)
IL (1) IL261998B2 (pl)
MX (1) MX2018012132A (pl)
PL (1) PL3439653T3 (pl)
PT (1) PT3439653T (pl)
RU (1) RU2745195C2 (pl)
SG (1) SG11201808626WA (pl)
TW (1) TWI808938B (pl)
WO (1) WO2017176965A1 (pl)
ZA (1) ZA201806633B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2928474T (pt) 2012-12-07 2019-01-30 Chemocentryx Inc Diazol lactamas
KR20170135860A (ko) 2015-03-13 2017-12-08 싸이톰스 테라퓨틱스, 인크. 항-pdl1 항체, 활성화 가능한 항-pdl1 항체, 및 이들의 사용 방법
JP7014706B2 (ja) 2015-07-13 2022-02-01 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
ES2864148T3 (es) 2016-04-07 2021-10-13 Chemocentryx Inc Reducción de la carga tumoral mediante la administración de los antagonistas de CCR1 en combinación con inhibidores de PD-1 o inhibidores de PD-L1
KR102401963B1 (ko) 2016-06-27 2022-05-25 케모센트릭스, 인크. 면역조절제 화합물
JP6501171B2 (ja) * 2017-03-29 2019-04-17 塩野義製薬株式会社 癌治療用医薬組成物
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
US10919852B2 (en) 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
CN111225665B (zh) 2017-08-08 2023-12-08 凯莫森特里克斯股份有限公司 大环免疫调节剂
BR112020012241A2 (pt) * 2017-12-22 2020-11-24 Codagenix Inc. vírus recombinante com a região não otimizada com codon-par e usos para o tratamento do câncer
WO2019165043A2 (en) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
WO2019240871A1 (en) * 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with s-equol
EP3843711A4 (en) * 2018-08-29 2022-08-03 ChemoCentryx, Inc. METHODS OF CANCER TREATMENT WITH SMALL MOLECULE PD-L1 INHIBITORS
TW202024638A (zh) * 2018-09-04 2020-07-01 美商泰沙羅公司 治療癌症之方法
JP2022501361A (ja) 2018-09-19 2022-01-06 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｃｄ８０融合タンパク質および関連構築物の方法および使用
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
WO2020102375A1 (en) 2018-11-14 2020-05-22 Regeneron Pharmaceuticals, Inc. Intralesional administration of pd-1 inhibitors for treating skin cancer
CA3137361A1 (en) 2019-02-28 2020-09-03 Regeneron Pharmaceuticals, Inc. Administration of pd-1 inhibitors for treating skin cancer
SG11202109003QA (en) 2019-03-06 2021-09-29 Regeneron Pharma Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
WO2021007386A1 (en) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes as pd-l1 inhibitors
GB201918692D0 (en) 2019-12-18 2020-01-29 Cambridge Entpr Ltd Treatment and prognosis of pancreatic cancer
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
CA3168738A1 (en) 2020-05-26 2021-12-02 Matthew G. Fury Methods of treating cervical cancer by administering a pd-1 inhibitor
CN116134155A (zh) 2020-08-26 2023-05-16 瑞泽恩制药公司 通过施用pd-1抑制剂治疗癌症的方法
JP2023542490A (ja) 2020-09-03 2023-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｄ－１阻害剤を投与することによりがん疼痛を処置する方法
JP2023545444A (ja) * 2020-10-13 2023-10-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 膵管腺癌を処置するための併用免疫療法および組成物
KR20230159590A (ko) 2021-03-23 2023-11-21 리제너론 파아마슈티컬스, 인크. Pd-1 억제제를 투여함에 의한 면역억제 또는 면역손상된 환자에서 암을 치료하는 방법
WO2023004287A1 (en) 2021-07-19 2023-01-26 Regeneron Pharmaceuticals, Inc. Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
WO2023159102A1 (en) 2022-02-17 2023-08-24 Regeneron Pharmaceuticals, Inc. Combinations of checkpoint inhibitors and oncolytic virus for treating cancer

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2229617A1 (en) 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE19539091A1 (de) 1995-10-20 1997-04-24 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
US6756385B2 (en) 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
AU2001290258A1 (en) 2000-09-22 2002-04-02 Nihon Nohyaku Co. Ltd. N-(4-pyrazolyl)amide derivatives, chemicals for agricultural and horticultural use, and usage of the same
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7396935B2 (en) 2003-05-01 2008-07-08 Bristol-Myers Squibb Company Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
CA2609051A1 (en) 2005-05-19 2006-11-23 Cv Therapeutics, Inc. A1 adenosine receptor agonists
US7777035B2 (en) * 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
CA2612552C (en) * 2005-06-22 2015-03-24 Chemocentryx, Inc. Azaindazole compounds and methods of use
FR2887450B1 (fr) 2005-06-23 2007-08-24 Rhodia Chimie Sa Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques
JPWO2007026834A1 (ja) 2005-09-01 2009-03-12 クミアイ化学工業株式会社 ピラゾール誘導体及び農園芸用除草剤
WO2007073432A2 (en) 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
US20090252779A1 (en) 2006-06-22 2009-10-08 Chemocentryx, Inc. Azaindazole compounds and methods of use
EP2079728B1 (en) 2006-10-10 2013-09-25 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
US20100113776A1 (en) 2006-12-14 2010-05-06 Taisho Pharmaceutical Co.,Ltd. Pyrazole derivative
US7786157B2 (en) 2007-03-16 2010-08-31 Chemocentryx, Inc. OXO-imidazolidines as modulators of chemokine receptors
EA015529B1 (ru) 2007-05-22 2011-08-30 Кемосентрикс, Инк. 3-(имидазолил)пиразоло[3,4-b]пиридины
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
CN101801362B (zh) 2007-06-22 2014-01-22 海德拉生物科学公司 用于治疗病症的方法和组合物
CA2705502C (en) 2007-11-13 2016-01-26 Taisho Pharmaceutical Co., Ltd. Phenylpyrazole derivatives
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP2297112B1 (en) 2008-05-06 2013-04-03 Boehringer Ingelheim International GmbH Pyrazole compounds as ccr1 antagonists
WO2009140519A1 (en) 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
ES2536884T3 (es) * 2008-09-11 2015-05-29 Chemocentryx, Inc. 4-Amino-3-(imidazolil)pirazol[3,4-d]pirimidinas
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
GB0915892D0 (en) 2009-09-10 2009-10-14 Smithkline Beecham Corp Compounds
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US9096642B2 (en) 2011-06-08 2015-08-04 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
DK2785375T3 (da) 2011-11-28 2020-10-12 Merck Patent Gmbh Anti-pd-l1-antistoffer og anvendelser deraf
CN104159911A (zh) 2012-03-07 2014-11-19 奥瑞基尼探索技术有限公司 作为免疫调节剂的模拟肽化合物
KR20140142736A (ko) 2012-03-29 2014-12-12 오리진 디스커버리 테크놀로지스 리미티드 인간의 pd1의 bc 루프로부터의 면역조절 사이클릭 화합물
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
AU2013267267B2 (en) 2012-05-31 2017-10-26 Genentech, Inc. Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
KR102103188B1 (ko) * 2012-08-27 2020-04-23 케모센트릭스, 인크. 케모카인 수용체의 길항제
PT2928474T (pt) * 2012-12-07 2019-01-30 Chemocentryx Inc Diazol lactamas
JP6306607B2 (ja) * 2012-12-21 2018-04-04 ケモセントリックス，インコーポレイティド ジアゾールアミド
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
KR20160030936A (ko) * 2013-07-16 2016-03-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
WO2015026634A1 (en) 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
CA2923184A1 (en) 2013-09-04 2015-03-12 Bristol-Myers Squibb Company Compounds useful as immunomodulators
KR20160075506A (ko) 2013-09-06 2016-06-29 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서 사이클릭 펩티도미메틱 화합물
JP2016532711A (ja) 2013-09-06 2016-10-20 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 免疫調節剤としての１，３，４−オキサジアゾール及び１，３，４−チアジアゾールの誘導体
PL3363790T3 (pl) 2013-09-06 2020-07-27 Aurigene Discovery Technologies Limited Pochodne 1,2,4-oksadiazolu jako immunomodulatory
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EP3904388A1 (en) * 2014-05-27 2021-11-03 Academia Sinica Fucosidase from bacteroides and methods using the same
WO2016011160A1 (en) * 2014-07-15 2016-01-21 Genentech, Inc. Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
MA40132B1 (fr) 2014-09-11 2019-04-30 Bristol Myers Squibb Co Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
MX2017011614A (es) 2015-03-10 2018-03-23 Aurigene Discovery Tech Ltd Compuestos de 1,3,4-oxadiazol y tiadiazol como inmunomoduladores.
CA3220902A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
SG11201706901TA (en) 2015-03-10 2017-09-28 Aurigene Discovery Tech Ltd Therapeutic cyclic compounds as immunomodulators
WO2016142894A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
CN107427476A (zh) 2015-03-10 2017-12-01 奥瑞基尼探索技术有限公司 作为免疫调节剂的3‑取代的‑1,2,4‑噁二唑和噻二唑化合物
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
ES2864148T3 (es) 2016-04-07 2021-10-13 Chemocentryx Inc Reducción de la carga tumoral mediante la administración de los antagonistas de CCR1 en combinación con inhibidores de PD-1 o inhibidores de PD-L1

Also Published As

Publication number Publication date
EP3439653B1 (en) 2021-01-20
BR112018070361A2 (pt) 2019-01-29
US20200289472A1 (en) 2020-09-17
EP3439653A1 (en) 2019-02-13
RU2018138828A3 (pl) 2020-08-12
IL261998B (en) 2022-11-01
KR102370704B1 (ko) 2022-03-03
CN109310677A (zh) 2019-02-05
WO2017176965A1 (en) 2017-10-12
AU2017246460A1 (en) 2018-10-25
EP3439653A4 (en) 2019-12-04
TW201801724A (zh) 2018-01-16
IL261998A (en) 2018-10-31
MX2018012132A (es) 2019-03-28
SG11201808626WA (en) 2018-10-30
RU2745195C2 (ru) 2021-03-22
CA3019391A1 (en) 2017-10-12
ES2864148T3 (es) 2021-10-13
ZA201806633B (en) 2021-04-28
DK3439653T3 (da) 2021-03-29
US20170290808A1 (en) 2017-10-12
KR20190020291A (ko) 2019-02-28
RU2018138828A (ru) 2020-05-15
JP2019510832A (ja) 2019-04-18
PT3439653T (pt) 2021-03-25
JP2022130424A (ja) 2022-09-06
AR108202A1 (es) 2018-07-25
AU2017246460B2 (en) 2021-04-22
US11744822B2 (en) 2023-09-05
TWI808938B (zh) 2023-07-21
US10568870B2 (en) 2020-02-25
IL261998B2 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
ZA201806633B (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
HK1249524A1 (zh) 用於治療血載癌症的免疫檢查點抑制劑
IL276314A (en) Preparations for the treatment of cancer using PD-1 axis binding antagonists and MEK inhibitors
IL252251A0 (en) Combined treatment including ox40 binding agonists and axispd-1 binding antagonists
IL249133B (en) A method for treating cancer with antagonists against pd-1 and pd-l1 in combination with radiation therapy
IL256085B (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
IL256166B (en) Compounds for use in the treatment of neuromuscular disorders
ZA201608077B (en) Combination, composition, and method of administering the combination or composition to animals
MX2016012021A (es) Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
IL263110A (en) Combined treatment of notch and pd-1 or pd-l1 inhibitors
IL247589A0 (en) Dihydropyridine mgat2 inhibitors for use in the treatment of metabolic disorders
IL246855A0 (en) Materials for use in the treatment of retinitis
EP3223793A4 (en) Compositions and methods for delivering a bio-active agent or bio-active agents
PL3509512T3 (pl) Kaniula do stosowania do wstrzyknięć śródkostnych
HK1232128A1 (zh) 用於預防或治療皮疹的藥物組合物
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
IL253933A0 (en) History of pyrimidine use in the treatment of cancer
EP3291818A4 (en) Compositions and methods for delivering therapeutic agents into the colon
EP3194030A4 (en) Substituted phenylpyrrolecarboxamides with therapeutic activity in hiv